Clinical Trial

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Study acronym: STOP KNEE-OA
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-12-18; most recent amendment 2025-04-27.
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06191848
Lead Sponsor University of Melbourne
Collaborators: Eli Lilly and Company
Conditions Obesity, Knee Osteoarthritis, Osteoarthritis, Knee
Enrollment 352 participants
Start Date 2024-11-19
Primary Completion 2027-05 (estimated)
Study Completion 2037-05 (estimated)
Updated on ClinicalTrials.gov 2025-04-30